ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1721

Investigating the SCF/c-Kit Pathway in Scleroderma Fibrosis

Bahja Ahmed Abdi1, Oseme Etomi2, Xu Shiwen1, David Abraham3, Christopher Denton3 and Richard J. Stratton1, 1Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 2Rheumatology, UCL Medical School, London, United Kingdom, 3Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Stem cell factor (SCF) is a potential driving factor in the development of systemic sclerosis (SSc) and a possible therapeutic target. SCF is a cytokine which acts via c-Kit, a tyrosine kinase receptor, present on the surface of progenitor cells, mast cells and melanocytes. This relationship with mast cells potentially drives pruritus, an under-reported but significant problem in SSc, which can suggest disease activity. The greatly altered pigmentation seen in SSc may also reflect altered SCF/c-Kit signalling affecting melanocytes. Previous work from our laboratory has demonstrated increased levels of SCF and c-kit in SSc fibroblasts compared to healthy controls Our aim was to measure the activity of SCF/c-Kit pathway in Systemic sclerosis.

Methods: Blister fluid, tissue and plasma samples were harvested from healthy controls (HC) and SSc patients. The SCF and c-Kit protein levels in SSc and HC lung fibroblasts were determined by western blotting. SCF (soluble and membrane bound) and c-kit gene expression was measured using quantitative PCR (qPCR) from control and SSc lung fibroblasts and epidermal sheet. The levels of SCF and c-Kit in SSc and HC were assessed by ELISA. The expression of CD117 positive lung fibroblasts was analysed by FACS.

Results: The soluble SCF mRNA expression was enhanced in SSc lung fibroblast samples by qPCR compared to healthy controls (soluble transcript: 23 versus 10 copy number respectively p=0.008 and membrane bound: 1.1 versus 0.7 p=NS). C-kit was expressed at low levels in both SSc and HC fibroblasts (0.31 versus 0.28 copy number, p=NS). Western blotting showed increased SCF protein levels in SSc lung fibroblasts compared to controls with relative density scan of 2.25 and 0.76 respectively (p=0.009) while the level of c-Kit protein expression was low in both SSc and control fibroblasts (0.16 vs 0.25) p=NS. Furthermore, measuring the epidermal sheet for SCF gene expression in SSc and HC showed that the soluble SCF isoform had 537 and 366 copy number respectively, while the membrane bound isoform showed gene copy numbers of 106 for SSc and 134 for HC. Using ELISA, SCF plasma levels were found to be lower in SSc patients (1272pg/ml) than the HC group (1425pg/ml) p=0.04, as were the plasma c-Kit levels (13ng/ml versus 16ng/ml respectively) p=0.028. Levels of SCF in conditioned media of cultured lung fibroblasts were higher in SSc (150ng/ml) vs HC (130ng/ml) p=0.002 but lower in blister fluid 1223pg/ml vs 1414 pg/ml respectively. C-Kit was undetectable in conditioned media and blister fluid.  A subpopulation of CD117 positive cells was found in both SSc and HC lung fibroblasts (1.26% SSc cells, 2.3% HC).

Conclusion: We demonstrated that the full length soluble SCF mRNA is found at higher levels in the epidermis and in the lung fibroblasts of SSc subject and that SCF appears at slightly higher levels in SSc fibroblast conditioned media. However, when measured in plasma or blister fluid SCF was lower or unaltered in SSc when compared to controls. Cultured fibroblasts were heterogeneous and only a minority were positive for c-Kit.  If SCF is important in SSc pathogenesis then it might be acting locally on a small subpopulation of c-Kit positive cells.  


Disclosure:

B. Ahmed Abdi,
None;

O. Etomi,
None;

X. Shiwen,
None;

D. Abraham,
None;

C. Denton,
None;

R. J. Stratton,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/investigating-the-scfc-kit-pathway-in-scleroderma-fibrosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology